FDA Adcomm Reforms Brewing Amid Decline in Meetings and High Compliance Rate

New research indicates a decline in the number of advisory committee meetings held by the FDA in recent years, with a decrease in meetings involving votes on initial drug approvals. The FDA is exploring reforms to ensure more timely and sound advice, and the agency's commissioner has suggested there may be fewer votes at future meetings.